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Abstract. 
 
Tenascin is a large extracellular matrix mole-
cule expressed at specific sites in the adult, including 
immune system tissues such as the bone marrow, thy-
mus, spleen, and T cell areas of lymph nodes. Tenascin 
has been reported to have both adhesive and anti-adhe-
sive effects in static assays. We report here that tenas-
cin supports the tethering and rolling of lymphocytes 
and lymphoblastic cell lines under flow conditions. 
Binding was calcium dependent and was not inhibited 
by treatment of lymphocytes with 
 
O
 
-glycoprotease or a 
panel of glycosidases including neuraminidase and hep-
aritinase but was inhibited by treatment of cells with 
proteinase K. Binding was to the fibrinogen-like termi-
nal domain of tenascin as determined by antibody 
blocking studies and binding to recombinant tenascin 
proteins. When compared to rolling of the same cell 
type on E-selectin, rolling on tenascin was found to be 
smoother at all shear stresses tested, suggesting that 
cells formed a larger number of bonds on the tenascin 
substrate than on the E-selectin substrate. When pro-
tein plating densities were adjusted to give similar pro-
files of cell detachment under increasing shears, the 
density of tenascin was 8.5-fold greater than that of 
E-selectin. Binding to tenascin was not dependent on 
any molecules previously identified as tenascin recep-
tors and is likely to involve a novel tenascin receptor on 
lymphocytes. We postulate that the ability of tenascin 
to support lymphocyte rolling may reflect its ability to 
support cell migration and that this interaction may be 
used by lymphocytes migrating through secondary lym-
phoid organs.
 
T
 
enascin
 
 is a large extracellular matrix (ECM)
 
1
 
 pro-
tein expressed in tissues of the immune system, in-
cluding the bone marrow (37), thymus (32), and the
T cell areas of secondary lymphoid organs (11). Tenascin
is also expressed in other sites in the adult including tu-
mors (24) and healing wounds (64, 65) and in restricted
patterns in the developing embryo (24). Tenascin hexam-
erizes to form a six-armed structure, or hexabrachion (26).
The arms consist of a distinctive pattern of four types of
protein motifs that form independently folding globular
domains. The NH
 
2
 
-terminal portion of the tenascin arm
contains cysteine residues used in oligomerization, fol-
lowed by a series of domains homologous to EGF, a series
of fibronectin type III (FN-III) domains, and a fibrinogen-
like terminal knob (fbg). Two other members of the ten-
ascin family, tenascin-R and tenascin-X, have been de-
scribed more recently; tenascin-R is expressed mainly in
the central nervous system, and tenascin-X is expressed
mainly in muscle, testis, and adrenal gland (10, 29, 45).
The cell adhesion activity of tenascin has produced some
controversial results in which the whole molecule and
smaller segments promote either adhesion or anti-adhe-
sion for different cell types. Recent studies using bacterial
expression proteins have identified two major cell adhe-
sion sites in the tenascin molecule that promote adhesion
of a broad range of cell types (see Fig. 3 for the domain
structure of tenascin). The third FN-III domain binds
three different integrins and mediates adhesion of several
cell types (5, 35, 46, 52, 66). The fibrinogen domain medi-
ates adhesion of fibroblasts via a cell surface proteoglycan
(5), endothelial cells via an integrin (35), and a variety of
other cells (46). In addition to these two sites, neurons can
bind to FN-III domains 1–2, 7–8, and the alternatively
spliced domains (22, 30, 46).
Peripheral blood leukocytes have not previously been
demonstrated to bind tenascin in a cell adhesion assay, but
there are indications that lymphocyte interactions with tena-
scin may be important. Tenascin is prominently expressed
in the reticular fibers of secondary lymphoid tissues, in-
cluding lymph node, spleen, Peyer’s patch, tonsil, and ap-
pendix (11, and Clark, R.A., and T.A. Springer, unpub-
lished observations). Secondary lymphoid organs experience
a constant influx and efflux of migrating lymphocytes that
enter via afferent lymph and by transmigration across
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Abbreviations used in this paper
 
: ECM, extracellular matrix; fbg, fibrin-
ogen-like terminal knob; FN-III, fibronectin type III; HEV, high endothe-
lial venule.
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HEV, transit through the lymph node compartments, and
finally exit via efferent lymphatics. It has been suggested
that lymphocytes may migrate along the reticular fiber
network of secondary lymphoid organs using adhesive in-
teractions with the ECM components of these fibers (14,
15, 38). Soluble tenascin has been shown to block T cell ac-
tivation in two independent studies (33, 50). Bone marrow
cells have been shown to adhere to whole tenascin (37),
but that study reported no adhesion of peripheral blood
leukocytes. In the present study we demonstrate that pe-
ripheral blood leucocytes and several cell lines, especially
of T cell lineage, can form low-avidity and transient adhe-
sions to tenascin that will produce tethering and rolling un-
der flow. We have mapped the adhesive domain on tenas-
cin and characterized the interaction relative to other
rolling adhesions. We discuss the potential utility of this
transient interaction for cell migration through the tenas-
cin-rich secondary lymphoid tissues.
 
Materials and Methods
 
Proteins
 
Purified tenascin-C and purified recombinant proteins TNfn1-5, TNfnA-D,
TNfn6-8, and TNfbg were produced as previously described (5). The bac-
terial recombinant protein TNfn6-8fbg comprises FN-III repeats 6–8 and
the fibrinogen domain (16). For use in flow studies, a 25-
 
m
 
l spot of tenas-
cin (50 
 
m
 
g/ml) or E-selectin (indicated dilution of column elution fraction)
in PBS were coated on 100 
 
3
 
 15 mm plastic Petri dishes (Nunc, Inc., Na-
perville, IL) overnight at 4
 
8
 
C. The spot and surrounding area were then
blocked with 2% human serum albumin (HSA; Calbiochem, San Diego,
CA) in HBSS for 2 h at 37
 
8
 
C, rinsed once with HBSS, and stored in HBSS
at 4
 
8
 
C until use. For adsorbing recombinant fragments of tenascin, a 25 
 
m
 
l
spot of control IgG CBRp150/2E1 (100 
 
m
 
g/ml) in PBS was first pread-
sorbed to 100 
 
3
 
 15 mm plastic Petri dishes for 1 h at 37
 
8
 
C. Recombinant
protein (50 
 
m
 
g/ml in 200 
 
m
 
l) was then incubated on the identical spot over-
night at 4
 
8
 
C. The spot and surrounding area were subsequently blocked
with 2% HSA in HBSS for 2 h at 37
 
8
 
C. Finally, the plate was rinsed with
HBSS and stored at 4
 
8
 
C until use. Substrates produced by coating of re-
combinant proteins without the preabsorption of a nonspecific protein,
e.g., IgG, gave no cell adhesion. No cell adhesion was observed on plates
coated only with control IgG and blocked with HSA.
 
Antibodies
 
PUJ4 (
 
a
 
4
 
 integrin mAb) and PUJ5 (
 
a
 
5
 
 integrin mAb) were both kind gifts
of Dr. M. Hemler (Dana-Farber, Boston, MA), DREG 56 was a kind gift
of Dr. T.K. Kishimoto (Boehringer Angelheim, Ridgefield, CT), mAb 13
(
 
b
 
1 integrin mAb) was kindly provided by Dr. K. Yamada (National Insti-
tutes of Health, Bethesda, MD). mAbs P1E6 (
 
a
 
2
 
 integrin mAb) and
P4C10 (
 
b
 
1
 
 integrin mAb) and polyclonal antibody to the 
 
a
 
v
 
 integrin sub-
unit and to tenascin were purchased from GIBCO BRL (Gaithersburg,
MD); additional samples of the P1E6 and P4C10 mAbs were obtained
from the Fifth International Workshop on Human White Cell Differentia-
tion Antigens. 4B4 (
 
b
 
1
 
 integrin mAb) was purchased from Coulter Corp.
(Hialeah, FL). Rabbit antibodies were prepared to purified recombinant
proteins TNfn1-5, TNfnA-D, and a mixture of TNfn6-8 plus TNfbg (5).
TNfn1-5 and TNfnA-D were injected at 50 
 
m
 
g/rabbit in complete Freund’s
adjuvant (subcutaneously at six sites), followed by three boosts with 10
 
m
 
g. The TNfn6-8 plus TNfbg mixture contained 100 
 
m
 
g of each protein for
the first injection and 50 
 
m
 
g each for the boosts, because one attempt at
the lower concentration gave no response. mAbs against tenascin, M112
(IgM), M139 (IgG
 
1
 
), M168 (IgG
 
1
 
), and M171 (IgM) and control mAb V60
(IgM) recognizing an irrelevant protein were produced by immunizing
mice with human tonsillar stromal preparations and screening the result-
ing mAb by immunohistochemistry on sections of human tonsil. The pro-
tocol for fusion and hybridoma maintenance has been described else-
where in detail (55). M112, M139, M168, and M171 recognize tenascin, as
evidenced by their immunohistochemical reactivity patterns in tonsil, mes-
enteric lymph node, spleen, colon, thymus, appendix, breast, and skin, rec-
ognition of immobilized tenascin in dot blots, and immunoprecipitation of
radiolabeled tenascin (data not shown). By immunohistochemistry, the
V60 mAb reacted only with phagocytic vacuoles in tingible body mac-
rophages in all tissues tested. CBRp150/2E1 (57) to p150,95 was used as a
control mAb in flow antibody blocking assays, and TS1/18 was used to the
 
b
 
2
 
 integrin subunit. All other mAbs were obtained from the Fifth Interna-
tional Workshop on Human White Cell Differentiation Antigens. mAb to
 
a
 
 integrin subunits from the Fifth Leukocyte Workshop were IB3.1 (
 
a
 
1
 
),
Gi9 (
 
a
 
2
 
), J143 (
 
a
 
3
 
), and LM609 (
 
a
 
v
 
b
 
3
 
). The mAb to CD44 was BRIC235.
For inhibition of binding to tenascin in flow, input cells were incubated 40
min on ice with a 1:20 dilution of mAb from the Fifth International Work-
shop on Leukocyte Differentiation Antigens, 1:1,000 dilution of PUJ4,
PUJ5, and P1E6 ascites, 1:500 P4C10 ascites, 1:200 dilution of rabbit anti-
sera, 1:100 dilution of M168, M112, M171, and V60 ascites, 50 
 
m
 
g/ml of pu-
rified mAbs CBRp150/2E1, TS1/18, DREG 56, 4B4, and M139 and 25 
 
m
 
g/
ml of purified mAb 13. For studies using anti-tenascin antibodies, the anti-
body was added to the flow chamber and incubated for 10 min before the
addition of cells.
 
Isolation of Lymphocytes from Blood and Human Tonsil
 
Peripheral blood lymphocytes (49) and tonsillar lymphocytes (15) were
prepared as described.
 
Cell Lines
 
Lymphoblastoid cell lines HuT 78 (American Type Culture Collection,
Rockville, MD; TIB 161), Jurkat (American Type Culture Collection; TIB
153), JY 25, SKW3 (originally from Dr. P. Cresswell, Yale University
School of Medicine, New Haven, CT), NALM6 (originally from McCaf-
frey, R.), and Raji (American Type Culture Collection; CCL 86) and my-
elomonocytic cell lines HL-60 (American Type Culture Collection; CCL
240), KG-1a (American Type Culture Collection; CCL 246.1), HEL 92.1.7
(American Type Culture Collection; TIB 180), THP-1 (American Type
Culture Collection; TIB 202), and U937 (American Type Culture Collec-
tion; CRL 1593) were maintained in RPMI 1640 medium (JRH Bio-
sciences, Lenexa, KS), 10% fetal bovine serum (JRH Biosciences).
 
Flow Experiments
 
Cell tethering and rolling was measured in a parallel-plate flow chamber
the lower wall of which was a 100 
 
3
 
 15 mm plastic Petri dish containing
spots of immobilized protein (34, 41). All experiments were in HBSS with
2 mM Ca
 
2
 
1
 
 and 1 mM Mg
 
2
 
1
 
 unless otherwise described. Video micros-
copy, analysis of videotape, measurements of cell accumulation in shear
flow, and measurement of detachment of cells and rolling velocities were
as described (41). For all studies, a total of 2 
 
3
 
 10
 
6
 
 cells at a concentration
of 5 
 
3
 
 10
 
6
 
 cells/ml were used per experiment. Unless otherwise noted,
cells were accumulated for 40 s each at 0.27 and 0.53 dynes/cm
 
2
 
; adherent
cells were counted after the 0.53 dynes/cm
 
2
 
 accumulation step.
 
Enzyme Treatments
 
Cells (2 
 
3
 
 10
 
6
 
 cells in 200 
 
m
 
l) were treated with 20 
 
m
 
g/ml (0.03 U/ml)
chondroitinase ABC (from 
 
Proteus vulgaris
 
; Sigma Chemical Co., St.
Louis, MO), 0.01 U/ml of heparitinase I (from 
 
Flavobacterium heparinum
 
;
Sigma Chemical Co.), 1,000 U/ml of hyaluronidase (type IV-S from bo-
vine testes; Sigma Chemical Co.), 0.1 U/ml of neuraminidase (from 
 
Vibrio
cholerae
 
, Sigma Chemical Co.) with or without 0.5 U/ml of exo 
 
b
 
-galac-
tosidase (grade VIII from 
 
Escherichia coli
 
, Sigma Chemical Co.), 60 
 
m
 
g/ml
(0.3 U/ml) 
 
O
 
-glycoprotease (Accurate Chemical and Scientific Corpora-
tion, Westbury, NY), or 100 
 
m
 
g/ml proteinase K (GIBCO BRL) diluted in
RPMI 1640, 10 mM Hepes pH 7.4, 0.1% BSA for 40 min at 37
 
8
 
C. Addi-
tional experiments in which cells were incubated with enzymes for 60 min
produced identical results. In previous studies, use of chondroitinase ABC
and heparitinase I under identical conditions abolished hyaluronan-
dependent lymphocyte binding to stromal cell monolayers (15). Neuramini-
dase and 
 
O
 
-glycoprotease used under similar reaction conditions pre-
vented sialic acid- and mucin-dependent leukocyte binding (28, 47), and
galactose-dependent binding of MOLT-4 cells to thymic epithelial cells
via galectin-1 was inhibited using similar buffer conditions and 30-fold less
exo-
 
b
 
-galactosidase enzyme than used in these studies (7).
 
Immunoblots
 
Intact and recombinant tenascin proteins (1 
 
m
 
g/spot) were spotted onto
nitrocellulose and allowed to dry overnight at room temperature. Nitro- 
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cellulose strips were then blocked for 1 h with 1% BSA (GIBCO BRL) in
tris-buffered saline with 0.05% Tween-20 (TBST) and then incubated with
primary antibodies for 1 h at room temperature (1:200 dilution of antisera
or monoclonal ascites or 10 
 
m
 
g/ml of purified mAb M139 in TBST). Strips
were rinsed three times for 7 min each in TBST and incubated for 30 min
in a 1:1,000 dilution of alkaline phosphatase-conjugated goat anti–mouse
IgG
 
1
 
A
 
1
 
M or goat anti–rabbit Ig (Zymed Labs, Inc., So. San Francisco,
CA) in TBST. Strips were rinsed three times for 7 min each in TBST and
developed with Western blue-stabilized AP substrate (Promega Biotech,
Madison, WI). Reaction was stopped with distilled water.
 
Soluble Inhibitors
 
Chondroitin sulfate B from bovine mucosa (Sigma Chemical Co.), heparin
from porcine mucosa (Sigma Chemical Co.), GRGDSP peptide (GIBCO
BRL), or fibrinogen 
 
g
 
-chain peptide HHLGGAKQAGDV (Sigma Chem-
ical Co.) were added to the cell suspension and the flow chamber for 10
min before flow experiments and were present throughout the experi-
ments. EDTA (5 mM) or 10 mM EGTA plus 2 mM Mg
 
2
 
1
 
 were added to
cells immediately before the experiment and were also present in cell-free
rinse medium used in the experiment. For experiments using azide and
2-deoxy-
 
d
 
-glucose, cells were pretreated for 10 min at room temperature
with 0.1% azide and 50 mM 2-deoxy-
 
d
 
-glucose (Sigma Chemical Co.);
these inhibitors were also present throughout the experiments.
 
Quantitation of Binding Sites
 
Site densities for plastic-adsorbed E-selectin and tenascin were deter-
mined using radiolabeled mAb as previously described (42).
 
Immunohistochemistry
 
Human tonsils from tonsillectomies were obtained from Children’s Hospi-
tal (Boston, MA) or Massachusetts General Hospital (Boston, MA) and
snap frozen in liquid nitrogen. Cryostat sections (5 
 
m
 
m) were cut and fixed
in room-temperature acetone for 5 min. Sections were incubated for 45
min with a 10 
 
m
 
g/ml concentration of M168 in PBS, rinsed three times for
5 min each in PBS, 1% BSA (GIBCO BRL) and incubated for 30 min
with a 1:40 dilution of FITC-conjugated goat anti–mouse IgG
 
1
 
A
 
1
 
M
(Zymed Labs, Inc.). Sections were subsequently rinsed three times for 5
min each in PBS, 1% BSA, and mounted under glass coverslips (Fisher
Scientific, Pittsburgh, PA) using Fluoromount-G mounting media (South-
ern Biotechnology Assoc. Inc., Birmingham, AL). Sections were observed
by fluorescence microscopy and photographed immediately after staining.
 
Results
 
Plastic-adsorbed Tenascin Supports
Lymphocyte Rolling
 
Freshly isolated peripheral blood lymphocytes and tonsil-
lar lymphocytes introduced under flow adhered to plastic-
adsorbed tenascin at wall shear stresses of 0.27 and 0.53
dynes/cm
 
2
 
 (Fig. 1 
 
a
 
). In contrast, neutrophils from periph-
eral blood did not bind tenascin under flow. Adherent
lymphocytes began rolling immediately after binding to
the substrate and continued to roll as shear was increased.
Binding to tenascin was threefold higher for tonsillar than
for peripheral blood lymphocytes. Lymphocytes harvested
from tonsil tissue contain activated cells that express the
activation antigens CD26, CD30, CD39, CD69, CD70, and
CD71 (8, 21, 58). Because cell lines are useful models for
activated leukocytes, several cell lines were also evaluated
for their ability to form rolling attachments to tenascin
(Fig. 1 
 
a
 
). Most cell lines of T cell, B cell, and myeloid lin-
eage bound tenascin, but the efficiency of binding varied
widely. The SKW3 T lymphoblastoid cell line was chosen
for subsequent studies because of its robust binding to ten-
ascin under flow.
Figure 1. Cell accumulation on plastic-adsorbed tenascin. (a) Ability of various cell types to accumulate on tenascin under flow. Cells
were accumulated for 40 s each at 0.27 and 0.53 dynes/cm2. Cells were counted after the 0.53 dynes/cm2 accumulation step; all adherent
cells were rolled. One of two representative experiments is shown with the range indicated by bars. (b) Effects of inhibitors and enzyme
treatments on SKW3 cell accumulation on tenascin. SKW3 cells were treated for 10 min at 258C with either 0.1% azide and 50 mM
2-deoxyglucose (Azide1DOG), inclusion of 5 mM EDTA or 10 mM EGTA and 1 mM Mg21 in the assay, or treatment for 40 min at 378
with chondroitinase ABC, heparitinase, hyaluronidase, neuraminidase, neuraminidase and exo-b-galactosidase, O-glycoprotease, or
proteinase K. Control binding represents binding of control-treated cells to the same tenascin substrate immediately before binding of
treated cells. Mean values for two experiments are shown with the range indicated by bars. 
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The ability of SKW3 cells to form rolling adhesions was
completely blocked by inclusion of EDTA or EGTA plus
Mg
 
2
 
1
 
 in the rolling assay and was therefore calcium de-
pendent (Fig. 1 
 
b
 
). Likewise, the binding of all other cell
lines shown to tether and roll on tenascin was completely
abolished by EGTA plus Mg
 
2
 
1
 
 (data not shown). Treat-
ment of SKW3 cells with a panel of glycosidases and with
 
O
 
-glycoprotease failed to inhibit the ability of these cells
to bind, suggesting that the SKW3 cell ligand activity is not
dependent upon chondroitin sulfates, heparin, hyaluronan,
sialic acid residues, galactose, or mucin-like molecules (Fig.
1 
 
b
 
). However, treatment of SKW3 cells with proteinase K
decreased binding to tenascin by 64%; identically treated
cells analyzed by immunofluorescence flow cytometry
showed a 92% decrease in CD44 staining, a 31% decrease
in 
 
b
 
2
 
, and a 22% decrease in 
 
a
 
4
 
 integrin subunit staining.
The reduction in binding after proteinase K treatment sug-
gests that the tenascin ligand on SKW3 cells is either a
protein or a carbohydrate dependent on protein scaffold-
ing for presentation. Pretreatment of SKW3 cells with
0.1% sodium azide and 50 mM 2-deoxy-
 
d
 
-glucose inhibited
binding by 30%.
The ability of rolling SKW3 cells to accumulate on tena-
scin decreased with increasing shear stresses (Fig. 2 
 
a
 
) with
a profile similar to that seen for SKW3 cells on purified
hyaluronan (15). Accumulation was less efficient than was
seen with neutrophils (PMN) on E-selectin, where accu-
mulation was still evident at 1.6 dynes/cm
 
2
 
 and declined to
zero between 3 to 4.5 dynes/cm
 
2
 
 (48). Rolling velocities of
cells on tenascin increased with increasing wall shear stress
and were on the order of 10 
 
m
 
m/second (Fig. 2 
 
b
 
), similar
to the rolling velocities of PMN on E-selectin (48) but faster
than the rolling velocities of SKW3 cells on hyaluronan,
which were on the order of 1 
 
m
 
m/s (15). SKW3 cells rolling
on tenascin detached with increasing shear stress (Fig. 2 
 
c).
SKW3 cells detached from tenascin at lower wall shear
stresses than seen with PMN on E-selectin or SKW3 cells
on hyaluronan; at 35 dynes/cm2, 96% of adherent SKW3
cells on tenascin had detached, whereas only 60% of PMN
on E-selectin and 20% of SKW3 cells on hyaluronan had
detached, respectively (15, 48). The ability of cells to accu-
mulate in shear flow, rolling velocity, and resistance to de-
tachment depend not only on intrinsic properties of the re-
ceptor–ligand interaction (48) but also to some extent upon
the number of binding sites on the substrate, which is a
function of the concentration of proteins used during ad-
sorption to plastic. Therefore, the above observations de-
pend on the plating concentrations used in these studies
and are not necessarily general properties of the interac-
tion.
To determine if conventional static binding assays would
detect the interaction of SKW3 cells with tenascin, plastic-
adsorbed tenascin substrates identical to those used in the
flow assays were used in static experiments. Using a Petri
dish adhesion assay, with very mild washing conditions,
that detects shear-sensitive, i.e., low avidity, interactions of
integrins (18), SKW3 cells incubated with tenascin sub-
strates showed no binding at 30 min and ,1 bound cell/
1003 field at 1 h and at 90 min (data not shown). Thus,
while binding to tenascin is easily demonstrable using the
flow assay, it is not surprising that previous studies using
static assays have failed to observe adhesive interactions (37).
Lymphocyte Rolling Is Mediated by the Fibrinogen-like 
Terminal Knob of Tenascin
To determine the region of the tenascin molecule that
binds to lymphocytes under flow, we used a panel of anti-
Figure 2. Accumulation, rolling velocity, and resistance to detachment of SKW3 cells on tenascin. (a) Accumulation of SKW3 cells on
plastic-adsorbed tenascin at various shears. Cells introduced at a concentration of 5 3 106 cells/ml were accumulated for 40 s at the indi-
cated shear stresses in separate experiments. The mean values of two experiments are shown with the range indicated by bars. (b) Roll-
ing velocities of SKW3 cells initially accumulated on plastic-adsorbed tenascin for 40 s at 0.27 dynes/cm2. Velocity measurements were
done on all cells in the field; bars represent SEM for each measurement. (c) Detachment of SKW3 cells bound to plastic-immobilized te-
nascin under increasing shear. Cells were initially accumulated for 40 s at 0.27 dynes/cm2 and then perfused with cell-free medium for 10 s at
each of the indicated shears. Cell accumulation at the end of the 0.27 dynes/cm2 accumulation step was considered 100% binding; the
numbers of cells remaining at the end of subsequent steps were compared to this value to determine percent detachment. The mean val-
ues of two experiments are shown; bars representing the range of measurements are present but are too small to be seen.Clark et al. Tenascin Supports Lymphocyte Rolling 759
bodies against tenascin. Rabbit polyclonal antibodies were
prepared against recombinant tenascin fragments TNfn1-5,
TNfnA-D, and TNfn6-81TNfbg (Fig. 3). Monoclonal anti-
bodies recognizing tenascin were produced by immunizing
mice with preparations of human tonsillar stroma. mAbs
were screened by immunohistochemistry, and those that
recognized high endothelial venule (HEV) or ECM com-
ponents of secondary lymphoid organs were further ana-
lyzed. A significant proportion of mAbs made in this way
was found to recognize tenascin. The sites of antibody
binding to tenascin were mapped by immunoblotting of
recombinant tenascin proteins (Fig 4 a). Rabbit antibodies
showed the expected specificity, and additionally, antibodies
to TNfn6-81TNfbg crossreacted weakly with TNfnA-D and
TNfn1-5. mAbs M139 and M171 were specific for TNfn1-5,
and mAb M112 reacted with TNfn1-5 and more weakly
with TNfn6-8fbg and TNfbg. mAb M168 reacted with
TNfn6-8fbg and TNfbg and not with TNfn6-8 and there-
fore appears specific for the fibrinogen-like terminal do-
main of tenascin. Antisera produced by immunizing rab-
bits with the TNfn1-5 and TNfnA-D tenascin proteins had
little effect on the binding of SKW3 cells to intact tenascin
under flow, while antisera raised against the TNfn6-8fbg
recombinant tenascin protein completely blocked binding
(Fig. 4 b). Antibodies M112, M139, and M171 to TNfn1-5
domains of tenascin did not significantly inhibit SKW3 cell
binding. By contrast, mAb M168 to the terminal fbg do-
main of tenascin reduced binding by 99%. These studies
suggest that the terminal fibrinogen-like domain of tena-
scin is responsible for binding to SKW3 cells.
To determine if recombinant tenascin proteins could
support rolling, we immobilized the proteins on plastic
precoated with nonspecific IgG and HSA (as described in
Materials and Methods) and used them as substrates in the
rolling assay. Rolling of SKW3 cells was observed on TNfbg
and TNfn6-8fbg but not on the other recombinant frag-
ments (Fig. 5). Overall levels of accumulation on recombi-
nant TNfbg was z10% of that observed with the intact
protein and was therefore considerably less efficient.
Binding to TNfn6-8fbg was even less efficient, perhaps re-
flecting reduced binding to IgG-coated plates. Transient
tethering, defined as cells that bound under flow and re-
mained adherent to the substrate for at least 1 s, was ob-
served at low levels for TNfnA-D, TNfn1-5, and TNfn6-8
and not for control substrates. Transient tethering of cells
to TNfn6-8fbg and TNfbg was two- and fivefold higher, re-
Figure 3. The domain structure of the hexabrachion arm of hu-
man tenascin (above) and the bacterial expression proteins used
in this study (below), modified from reference 5.
Figure 4. Localization of antibody binding sites with immunoblotting and inhibition of cell binding to tenascin. (a) Recognition of tena-
scin and recombinant tenascin proteins by antibodies. Proteins were spotted on nitrocellulose and detected with the indicated antibodies
and alkaline phosphatase–anti-Ig. Antibodies included normal rabbit serum (NRS); rabbit antibodies against intact tenascin (a-TN), re-
combinant TNfnA-D (a-TNfnA-D), recombinant TNfn1-5 (a-TNfn1-5), and a mixture of recombinant TNfn6-8 and TNfbg (TNfn6-
8fbg); a negative IgG control mAb; and mAb M112, M139, M168, and M171 against tenascin. (b) Inhibition of SKW3 cell binding to
plastic-adsorbed tenascin by tenascin antibodies. Binding of SKW3 cells was measured before and after treatment of the spots of plastic-
immobilized tenascin with polyclonal antisera (1:50), ascites (1:100), or purified mAb (50 mg/ml) for 10 min. Binding to control NRS-
treated spot was 250 cells and binding to IgG control-treated spot was 224 cells. Mean values of two experiments are shown, with the
range indicated by bars.The Journal of Cell Biology, Volume 137, 1997 760
spectively, than that seen with the other proteins. The re-
combinant tenascin fragments expressed in bacteria are
not glycosylated, and thus carbohydrate on tenascin is not
required for rolling adhesion. The observation that recom-
binant proteins containing the fibrinogen-like domain of
tenascin can support cell rolling, and the ability of antibod-
ies to this region to block rolling suggests that this domain
supports rolling of SKW3 cells.
Lymphocyte Rolling on Tenascin is Smoother Than 
Rolling on Selectins
The characteristics of tenascin-mediated rolling were com-
pared to rolling on E-selectin using KG1a cells, which bind
to both tenascin and E-selectin (28). To directly compare
the two adhesion systems, plating concentrations of E-selec-
tin were varied until the detachment profile of KG1a cells
on E-selectin was similar to that observed using a 50 mg/ml
plating concentration of tenascin (Fig. 6 a). This required
plating of purified E-selectin at concentrations 5- to 10-fold
lower than the amount used routinely for experiments in
our laboratory (42). At an E-selectin plating dilution of 1:
1,000, a level at which detachment from the two substrates
was most similar, the E-selectin substrate was found to
contain 34 sites/mm2, as measured by binding of radiola-
beled mAb CL3. In contrast, the tenascin substrate con-
tained 290 sites/mm2, as measured by binding of the func-
tion-blocking mAb M168. The tenascin substrate therefore
had 8.5-fold more binding sites than the E-selectin sub-
strate under conditions in which cells detached at roughly
the same shear stresses.
Figure 5. Ability of recombinant tenascin proteins to support
SKW3 cell rolling. Cells were accumulated for 40 s at 0.27 dynes/
cm2 shear stress; adhesion events were counted throughout this
40 s period. “Accumulation” represents cells that rolled a dis-
tance of at least four cell diameters. “Tethering events” were de-
fined as cells that tethered under flow and remained bound to the
substrate for at least one second. Mean values of two experiments
are shown, and the range is indicated by bars.
Figure 6. Comparison of KG1a cells rolling on tenascin and E-selec-
tin. (a) Detachment profiles of KG1a cells on tenascin and two
plating dilutions of E-selectin. (b) Rolling velocities of KG1a
cells on tenascin and E-selectin. The mean values of two experi-
ments are shown; ranges are indicated by bars.
KG1a cells on tenascin at 290 sites/mm2 rolled at similar
velocities to KG1a cells on a plating dilution of 1:500 E-selec-
tin (Fig. 6 b). During these experiments it was noted that
KG1a cells rolling on E-selectin appeared to move in a se-
ries of jerks, as previously noted for rolling on selectins
(3), whereas cells attached to tenascin rolled more smoothly.
We quantitated variation in rolling velocity using separate
conditions under which either the wall shear stress or the
average rolling velocity were identical on the three sub-Clark et al. Tenascin Supports Lymphocyte Rolling 761
strates. The position of representative rolling cells was
measured every 0.033 s. For each condition, both the dis-
placement (Fig. 7, top graph) and the velocity (Fig. 7, bot-
tom graph) are shown. A relatively straight tracing on the
displacement versus time graph indicates a cell that rolled
smoothly at a constant velocity, while a tracing with
changes in slope indicates a cell that rolled in a more jerky
manner. Similarly, the range of velocities for a smoothly
rolling cell is small, while the intermittent motion of a
jerky cell is reflected in a larger range of rolling velocities.
This was quantified by calculating the variance in cell ve-
locities for cells rolling on the three substrates. Cells roll-
ing on tenascin had a variance in velocities of 40.4, whereas
cells rolling on 1:1,000 and 1:500 dilutions of E-selectin had
larger variances, 425 and 104, respectively. Therefore, cells
rolled more smoothly on tenascin at 2.7 dynes/cm2 shear
stress than cells rolling on either site density of E-selectin
(Fig. 7, a–c). To compare cells rolling at a similar velocity
of 10 mm/s, cells rolling at 2.7 dynes/cm2 shear stress for
E-selectin (1:1,000) and at 10 dynes/cm2 for E-selectin (1:
500) and tenascin were compared (Figs. 6 b and 7, d–f).
Cells bound to tenascin rolled more smoothly than cells
bound to E-selectin when rolling at similar velocities. The
variance in cell velocities was 75.8 for cells rolling on tena-
scin and 425 and 246 for cells rolling on 1:1,000 and 1:500
dilutions of E-selectin, respectively. These direct compari-
sons suggest that the smoother rolling observed with tena-
scin is an inherent characteristic of the molecular interac-
tion of tenascin with its cellular receptor.
Rolling of Lymphocytes on Tenascin May Use a
Novel Receptor
More than a dozen molecules have been identified as tena-
scin receptors (Table I). Among them are a number of
members of the integrin family. Most notably, binding via
a2b1 may involve the fbg region of the tenascin molecule
(35, 56). We therefore investigated whether treatment of
SKW3 cells with blocking mAbs to these integrins would
inhibit tethering and rolling on tenascin. Two different
blocking mAbs to the b1 integrin had little or no effect on
attachment of SKW3 cells to tenascin (Fig. 8), as did a
third b1-blocking mAb, 4B4 (data not shown). Most signif-
icantly, the b1 mAb P4C10 obtained from two different
sources did not inhibit binding of SKW3 cells in the shear
flow assay despite reports that it blocks the binding of the
a2b1 integrin to tenascin (56). A panel of blocking anti-
bodies to the a1, a2, a3, a4, a5, a6, and av integrin subunits
also had no effect (Fig. 8); these included two different
samples of P1E6, the a2 mAb reported to inhibit a2b1 in-
teraction with tenascin (56). Furthermore, expression of
the a2 integrin subunit did not correlate with the ability of
cell lines to bind to tenascin. Hut 78 and Raji cell lines do
not express the a2 integrin subunit (53) but bind efficiently
to tenascin. The blocking avb3 mAb LM609 did not inhibit
SKW3 cell binding, despite its ability to inhibit tenascin
binding via avb3 (56), and a polyclonal antibody to the hu-
man av subunit did not inhibit binding despite its ability to
block av-mediated binding of human cell lines to chicken
tenascin (46). In addition, the RGD peptide GRGDSP, re-
ported to block a2b1 and avb3 binding to tenascin (35, 56),
also had no effect (Fig. 8). a2b1 is the only integrin thought
to interact with the fbg region of tenascin; other integrins
recognize tenascin’s FN-III repeats (Table I). These inte-
grins contain either av or b1 subunits; however, multiple
antibodies to these subunits failed to inhibit binding to tena-
scin in the flow assay.
Heparin binding to tenascin also involves tenascin’s fbg
Figure 7. Rolling on tenascin is smoother than rolling on E-selectin at all shear stresses examined. (a–c) Displacement and velocity pro-
files of cells rolling on tenascin and E-selectin at 2.7 dynes/cm2 shear stress. (c–e) Change in velocity profiles of cells rolling on tenascin
and E-selectin at 10 mm/s. The variance of velocity measurements is as shown.The Journal of Cell Biology, Volume 137, 1997 762
region (5, 27). In addition to the ability of tenascin to bind
purified heparin (5, 27, 63), the binding of tenascin to both
syndecan (51), a cell surface proteoglycan on fibroblasts
(5), and the proteoglycan glypican (62) is also heparin de-
pendent, as shown by the ability of heparitinase treatment
and/or soluble heparin to inhibit binding to these ligands.
Heparitinase treatment of SKW3 cells did not inhibit bind-
ing to tenascin at the recommended enzyme level of 0.01
U/ml (Fig. 1 b), nor did it when used at the much higher
doses of 0.05 and 0.1 U/ml (data not shown). Inclusion of
100 mg/ml heparin in the rolling assay also failed to inhibit
binding of SKW3 cells, and inclusion of 200 and 500 mg/ml
was not inhibitory relative to the inclusion of similar
amounts of a control, chondroitin sulfate B (data not
shown). In contrast, adhesion of fibroblasts to TNfbg was
inhibited by as little as 10 mg/ml heparin (5). In light of
these results we believe that the interactions we observe
with tenascin are not mediated by tenascin binding to hep-
arin or heparin-like structures on SKW3 cells.
The remaining identified tenascin ligands include an-
nexin II (12), a protein that binds tenascin via TNfnA-D;
fibronectin (13), which binds tenascin via TNfn3; neurocan
and phosphacan (6, 31, 44), two soluble chondroitin sulfate
proteoglycans specific to nervous tissue; contactin (62), a
neural cell adhesion molecule and a member of the immu-
noglobulin superfamily; and perlecan, a proteoglycan com-
ponent of basement membranes (Table I). None of these
molecules are known to be expressed on lymphocytes or
leukocyte cell lines, nor have any been reported to bind
via the fbg region of tenascin. To rule out contributions by
L-selectin and CD44, two molecules known to mediate
lymphocyte rolling (15, 17), we treated SKW3 cells with
mAbs known to block rolling via these molecules (15, 36);
these mAbs also had no effect (Fig. 8). The fbg region of
tenascin bears a 40% amino acid sequence homology to
fibrinogen (20), raising the question of whether known fi-
brinogen-binding molecules may be involved in lympho-
cyte binding to tenascin. Fibrinogen g-chain peptide HHL-
GGAKQAGDV has been reported to block the binding
of fibrinogen to platelets and endothelial cells (59), but it
had no effect on SKW3 cell binding to tenascin (data not
shown). ICAM-1 has also been reported to mediate bind-
ing of leukocytes and endothelial cells to fibrinogen (39).
However, ICAM-1 is present on both the cell lines that
bind tenascin, e.g., Raji and SKW3, and the cell lines that
do not bind tenascin, e.g., JY (53), suggesting that the
presence of ICAM-1 does not correlate with tenascin
binding. Adhesion in shear flow of lymphocytes and leu-
kocyte cell lines to tenascin may therefore involve a novel
receptor.
Discussion
Previous flow studies have demonstrated that two well-
known classes of molecules are capable of mediating roll-
ing: the selectins, E-selectin, L-selectin, and P-selectin
(54); and specific members of the integrin family, such as
VLA-4 that binds to VCAM-1 (2, 9), a4b7 that binds to
MAdCAM-1 (9), and a6b4 that binds to laminin (60). Re-
cently, it was found that hyaluronan, a component of the
ECM network of lymph nodes, mediated lymphocyte roll-
ing via CD44 (15, 17). We therefore investigated whether
Table I. Tenascin Receptors
Receptor Tenascin binding site Characteristics Reference
a2b1 Unknown, possibly TNfbg Blocked by b1 mAb P4C10 (35, 56)
and a2 mAb P1E6. Di-
valent cation dependent, 
RGD sensitive
a8b1 TNfn3 (52, 61)
a9b1 TNfn3 Not inhibited by RGD (66)
peptide or by mutating
RGD site
avb3 TNfn3 Inhibited by mAb LM609 (35, 56)
and RGD. Divalent 
cation dependent
avb6 TNfn3 Blocked by av polyclonal (46)
antibody
Annexin II TNfnA-D (12)
Contactin TNfn5 and TNfn6 Requires TNfn5 and TNfn6 (62)
to be adjacent
Fibronectin TNfn3 (13)
Glypican TNfn5 Blocked by heparin (62)
Heparin TNfbg, TNfn5 Cation and RGD insensitive (5, 27, 63)
Neurocan Unknown (31)
Perlecan TNfn3-5 (26a)
Phosphacan Unknown (6, 44)
Syndecan Unknown Abolished by heparitinase (51)
treatment by syndecan
Versican Unknown Calcium dependent, (4, 32)
(lectin domain) blocked by chemical de-
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other ECM components of secondary lymphoid organs
might also support binding of lymphocytes under flow. We
report here that tenascin mediates tethering and rolling of
lymphocytes and of lymphoid and myeloid cell lines. Al-
though tenascin has been shown to bind to fibroblasts and
other cell types (Table I), this is the first report of lympho-
cyte adhesion to tenascin. Using static binding assays, ten-
ascin has been shown to be both adhesive and anti-adhe-
sive, depending on the experimental conditions (24). Our
findings that tenascin mediates rolling may have implica-
tions for the mechanical nature of these particular tenas-
cin–ligand bonds and may explain why earlier studies of
lymphocyte binding using static assays did not detect these
interactions. Fast off rates have been shown for selectin-
mediated rolling, and most likely fast on-rates are also in-
volved (1). The receptor–ligand bonds involved in rolling
adhesions must be highly labile, with rapid formation and
dissolution of bonds, so that adhesions formed in the trail-
ing edge of the adhesive contact zone do not retard the cell
but instead release and allow the cell to roll forward and
form new adhesions at the leading edge. In our studies the
same plastic-adsorbed tenascin substrates used in the roll-
ing assays failed to support the binding of SKW3 cells in
conventional static binding assays. Thus static assays would
have produced a null result in this case. The sort of tran-
sient binding known to support cell rolling, and exempli-
fied best by the selectins, is not detected well by traditional
static assay systems and yet can play major roles in cell be-
havior in vivo.
Our studies showed that the fibrinogen-like terminal
knob of the tenascin molecule was responsible for tena-
scin’s ability to support rolling of SKW3 cells. Polyclonal
and monoclonal antibodies to this terminal domain com-
pletely blocked binding to native tenascin. Furthermore,
recombinant proteins containing the fibrinogen-like termi-
nal domain supported tethering and rolling of SKW3 cells.
Tenascin has been found in all vertebrates studied and has
remained remarkably conserved throughout evolution (25).
The fbg region of tenascin is perched on the COOH termi-
nus of the tenascin arm, while the NH2 terminus of the arm
contains domains that bind to the other monomers in the
hexabrachion. This is analogous to the positioning of the
binding domains of selectins and IgSF members that medi-
ate rolling at the membrane-distal ends of these molecules
and may facilitate accessibility for interactions in shear
flow.
Tenascin is expressed in several hematopoetic and lym-
phoid tissues including bone marrow (37), thymus (32),
spleen (43), lymph node, tonsil, and Peyer’s patches (11,
and Clark, R.A., unpublished observations). In the lymph
node and tonsil, tenascin is expressed in the reticular fi-
bers of the T cell areas as well as the basal surfaces of
HEVs, suggesting a role in cell migration as opposed to
lymphocyte binding to the luminal surface of HEVs (Fig.
9). Previous studies have suggested that during lympho-
cyte migration through secondary lymphoid organs, lym-
phocytes may migrate along the reticular fiber network via
adhesive interactions with the ECM components of these
fibers (14, 15, 38). Although the rolling adhesions that we
have demonstrated in vitro are not likely to occur in vivo
in secondary lymphoid organs, the dynamic nature of this
interaction may be well suited to support cellular migra-
tion. The dynamic reversibility of bonds formed between a
cell and the substrate is a key part of cellular migration
(23). Lymphocytes form bonds with tenascin that are suffi-
ciently strong to tether the cell to the substrate but not
Figure 8. Binding of SKW3 cells to tenascin is not inhibited by
mAbs to known tenascin ligands or RGD peptide. SKW3 cells
were treated with the indicated mAbs or GRGDSP peptide be-
fore flow assays; M168 and GRGDSP were also added to the flow
chamber before the addition of cells. For GRGDSP peptide ex-
periments, cells were maintained in the continued presence of the
peptide. Observed binding was compared to binding of cells
treated with control IgG CBRp150/2E1 (mAb experiments; con-
trol binding was 162 cells), normal rabbit serum (rabbit Ab; con-
trol binding was 171 cells), or untreated cells (GRGDSP peptide
experiments; control binding was 293 cells) to obtain percent con-
trol binding. The mean values of two experiments are shown;
ranges are indicated by bars.
Figure 9. Immunofluorescent staining of human tonsil with tena-
scin mAb M168. Tenascin is heavily expressed by HEV and the
reticular fiber network of the interfollicular T cell areas, while B
cell follicles show sparse expression. “F” denotes a B cell follicle;
three prominent HEV are visible below the follicle.The Journal of Cell Biology, Volume 137, 1997 764
strong enough to induce cell arrest and sticking. Migration
speed has been suggested to be biphasic with respect to at-
tachment strengths; low attachment strengths do not permit
the transmission of the motile force within the cell to the
substrate, intermediate attachment strengths produce the
fastest migration, and higher attachment strengths pro-
duce cell arrest and spreading (19, 40). Indeed, the speed
of smooth muscle cell migration on fibronectin and type
IV collagen substrates was found to be fastest at interme-
diate attachment strengths (19). Thus, we predict that the
ability of tenascin to support lymphocyte rolling may also
reflect the ability of this protein to support cellular migra-
tion. Alternatively, cells may simultaneously bind to tenas-
cin through a labile interaction that does not impede but
may help guide the direction of cell migration, and to
other extracellular matrix components through firmer ad-
hesive interactions that may provide traction for migration
but not directionality cues.
Quite aside from this possibility, the fact that tenascin
supports rolling provides interesting information about
the mechanics of this protein’s interaction with its recep-
tor. Rolling of cells on tenascin is smoother than rolling of
the same cell type on E-selectin at comparable rolling ve-
locity, wall shear stress, and resistance to detachment. This
suggests that a greater number of bonds is present between
the cell and the substrate on tenascin than on E-selectin; the
smoothness of rolling is thought to reflect small move-
ments of the cell upon dissociation of each bond, requir-
ing closer spacing between bonds and a greater number of
bond dissociation events per unit time. This is consistent
with the finding that a tenascin substrate that produced
cell binding with similar shear resistance to an E-selectin
substrate was found to have an 8.5-fold higher site density.
However, because the density and affinity of the receptors
on KG1a cells for E-selectin and tenascin are not known,
the number of receptor–ligand bonds may not be propor-
tional to the ligand density on the substrate.
The cellular receptor mediating the attachment of lym-
phocytes and leukocytic cell lines to tenascin under shear
flow remains unidentified. Because we have ruled out all
known tenascin receptors that interact with the fbg region
of tenascin and that may be expressed on lymphocytes, we
believe these interactions are mediated by a novel tenascin
receptor. Other receptors for tenascin have been charac-
terized with nonhematopoietic cell types; because nonhe-
matopoietic cells can also be used in rolling assays in shear
flow, it will be interesting to compare the different recep-
tors that bind tenascin for rolling in shear flow.
In addition to the interaction with tenascin described
here, laminin supports rolling via the integrin a6b4 (60),
and hyaluronan supports rolling via CD44 (15, 17). In ad-
dition to the molecules on cell surfaces known to support
rolling, our report brings to three the number of ECM
components that mediate leukocyte rolling.
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